Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
NCT01845259 on ClinicalTrials.gov · last registry update 2016-05-05
103 participants. The sponsor logged completion for March 2016. Primary outcome, as filed: Glucose tolerance. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Psychiatric Centre Rigshospitalet
- Sponsor type
- Other
- Enrollment
- 103
- Started
- 2013-04
- Primary completion
- 2016-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Glucose tolerance
Conditions studied
Impaired Glucose Tolerance Associated With Drugs
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.